The renoprotective effects of tadalafil on ischemia-reperfusion injury during partial nephrectomy in an animal model
Abstract
BACKGROUND: Although 25 min is the reported safe partial nephrectomy time for warm ischemia, acute kidney injury occurs even with arterial ligation within 25 min, causing serious complications in patients with chronic renal disease. Various drugs have been studied but evidence of their effectiveness and safety is insufficient. This study investigated the renoprotective function of tadalafil. METHODS: A rat model of partial nephrectomy was treated orally with tadalafil for 14 days before ischemic-reperfusion (IR) injury. Blood and kidney samples were collected for biochemical and molecular analyses 24 h after IR injury. The levels of serum blood urea nitrogen, creatinine, and urine kidney injury molecule-1 were analyzed, while kidney tissues were used for qPCR and histological analysis. RESULTS: Although effects on blood urea nitrogen and creatine levels were not observed, tadalafil preserved renal function by suppressing the decrease of viable glomeruli, indicating it protected kidneys from IR injury-induced glomeruli loss. Tadalafil effectively reduced the expression of the oxidative stress markers, inducible NOS, endothelial NOS, and myeloperoxidase, and significantly suppressed the expression of inflammation-related genes like TNF-α, IL-1β, IL-6, CD4, and CD8. CONCLUSIONS: Tadalafil inhibits oxidative stress and inflammation, and protects from glomeruli loss during ischemic-reperfusion damage in a rat model of partial nephrectomy. CLINICAL TRIAL NUMBER: Not applicable.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.